Table 3.
Effect of Pravastatin Treatment on Clinical Events by Each Quartile of Baseline Lp‐PLA2 Activity
| End Point | Lp‐PLA2 Activity (nmol/min per milliliter) | Placebo (5‐y rate, %) | Pravastatin (5‐y rate, %) | Hazard Ratio (95% CI) | NNT (Based on Common HR) | Interaction P Value Trend |
|---|---|---|---|---|---|---|
| CHD events (CHD death or nonfatal MI) | ≤229 | 10.9 | 9.1 | 0.83 (0.64, 1.07) | 45 | 0.36 |
| 229 to 261 | 11.7 | 11.3 | 0.86 (0.68, 1.09 | 42 | ||
| 261 to 294 | 12.6 | 9.5 | 0.73 (0.57, 0.93) | 39 | ||
| >294 | 16.1 | 12.3 | 0.74 (0.59, 0.92) | 31 | ||
| Major CVD events (CVD death, nonfatal MI, or stroke) | ≤229 | 14.0 | 12.1 | 0.83 (0.66, 1.04) | 35 | 0.27 |
| 229 to 261 | 14.3 | 13.6 | 0.89 (0.72, 1.10) | 34 | ||
| 261 to 294 | 16.9 | 11.6 | 0.66 (0.53, 0.83) | 29 | ||
| >294 | 19.7 | 15.5 | 0.75 (0.62, 0.91) | 25 | ||
| Total CVD events (major CVD, unstable angina, or revascularization) | ≤229 | 32.9 | 30.8 | 0.88 (0.76, 1.02) | 25 | 0.63 |
| 229 to 261 | 34.8 | 30.0 | 0.86 (0.74, 0.99) | 24 | ||
| 261 to 294 | 35.4 | 31.0 | 0.83 (0.72, 0.96) | 24 | ||
| >294 | 40.3 | 35.5 | 0.84 (0.74, 0.97) | 22 | ||
| CHD death | ≤229 | 5.1 | 3.5 | 0.73 (0.49, 1.08) | 87 | 0.84 |
| 229 to 261 | 5.8 | 6.0 | 0.84 (0.60, 1.16) | 77 | ||
| 261 to 294 | 6.4 | 4.3 | 0.68 (0.47, 0.96) | 70 | ||
| >294 | 8.4 | 7.2 | 0.81 (0.61, 1.08) | 54 | ||
| All‐cause mortality | ≤229 | 9.1 | 7.2 | 0.78 (0.59, 1.02) | 49 | 0.92 |
| 229 to 261 | 10.4 | 9.8 | 0.81 (0.63, 1.03) | 43 | ||
| 261 to 294 | 10.7 | 7.7 | 0.64 (0.49, 0.84) | 42 | ||
| >294 | 11.8 | 10.7 | 0.83 (0.65, 1.04) | 38 |
CHD indicates coronary heart disease; CVD, cardiovascular disease; HR, hazard ratio; Lp‐PLA2, lipoprotein‐associated phospholipase A2; MI, myocardial infarction, NNT, number needed to treat.